← Issue №6/ week of Aug 9, 2026/IBD

The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.

From GI Signals issue №6: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD review · Aug 13, 2026 · Inflamm Bowel Dis · IF 4.5

The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.

Guideline / reviewCrohn's diseaseulcerative colitismicrobiome
Clinical takeawayGLP-1 RAs are not yet established for IBD disease modification. Consider offering them to obese IBD patients (particularly those with metabolic comorbidities including MASLD or cardiovascular disease) primarily for obesity and comorbidity management, with close monitoring for gastrointestinal tolerability, coordination with endoscopy plans, and assessment of lean muscle mass preservation. Pending results of ongoing randomized trials evaluating disease-modifying effects.
What it foundPreclinical studies show that GLP-1 receptor agonists reduce visceral adiposity and attenuate proinflammatory signaling; emerging human data suggest they are safe in patients with IBD and associated with lower hospitalization and surgical rates in those with obesity, although effects on disease activity remain unclear.
ContextObesity affects over half of IBD patients and is associated with increased disease activity, reduced treatment response, and higher surgical risk. GLP-1 RAs have transformed obesity management in the general population and confer cardiovascular benefits. This review synthesizes preclinical mechanisms and emerging clinical safety data to support further investigation of GLP-1 RAs in IBD management.
Emergingsuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)

Decision at stakewhether to offer glucagon-like peptide-1 receptor agonists to overweight or obese patients with UC, particularly those with cardiometabolic comorbidities

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes) ↗
Beniwal-Patel P … Yarur AJ · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №6 Every paper GI Signals surfaces gets a page like this one. All issues